{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:11:27Z","timestamp":1789690287924,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-04985-8","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:19:16Z","timestamp":1782843556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of hepatotoxicity and lipid metabolism\u2013related toxicity on survival and quality of life in patients with high-volume metastatic hormone-sensitive prostate cancer treated with rezvilutamide in the CHART trial: a post hoc analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Jun-Long","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Suan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng-Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian-Zeng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Quan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Chen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Yi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Quan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Yi","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Gang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Wei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Po","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding-Wei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"3","key":"4985_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"4985_CR2","doi-asserted-by":"publisher","first-page":"e2440381","DOI":"10.1001\/jamanetworkopen.2024.40381","volume":"7","author":"M Li","year":"2024","unstructured":"Li M, Hu M, Jiang L, Pei J, Zhu C. Trends in Cancer Incidence and Potential Associated Factors in China. JAMA Netw Open. 2024;7(10):e2440381.","journal-title":"JAMA Netw Open"},{"key":"4985_CR3","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 1.2025. 2024."},{"issue":"10","key":"4985_CR4","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/S1470-2045(22)00507-1","volume":"23","author":"W Gu","year":"2022","unstructured":"Gu W, Han W, Luo H, Zhou F, He D, Ma L, et al. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 2022;23(10):1249\u201360.","journal-title":"Lancet Oncol"},{"issue":"12","key":"4985_CR5","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022;386(12):1132\u201342.","journal-title":"N Engl J Med"},{"key":"4985_CR6","doi-asserted-by":"publisher","first-page":"e17823","DOI":"10.7717\/peerj.17823","volume":"12","author":"T Zhuo","year":"2024","unstructured":"Zhuo T, Yao X, Mei Y, Yang H, Maimaitiyiming A, Huang X, et al. Effect of metabolic syndrome on testosterone levels in patients with metastatic prostate cancer: a real-world retrospective study. PeerJ. 2024;12:e17823.","journal-title":"PeerJ."},{"issue":"3","key":"4985_CR7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.euo.2024.05.013","volume":"8","author":"EY Yu","year":"2025","unstructured":"Yu EY, Ferrario C, Linch MD, Stoeckle M, Laguerre B, Arranz JA, et al. Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-na\u00efve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D. Eur. Urol Oncol. 2025;8(3):641\u201351.","journal-title":"Urol Oncol"},{"issue":"1","key":"4985_CR8","first-page":"405","volume":"16","author":"X Xu","year":"2025","unstructured":"Xu X, Zhu W, Peng Y. Causal associations between liver function biomarkers and prostate cancer risk in European and East Asian populations: a univariate, multivariable, and bidirectional Mendelian Randomization study. Discov. Oncol. 2025;16(1):405.","journal-title":"Oncol."},{"issue":"1","key":"4985_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4111-5","volume":"18","author":"C Bosco","year":"2018","unstructured":"Bosco C, Garmo H, Hammar N, Walldius G, Jungner I, Malmstr\u00f6m H, et al. Glucose, lipids and gamma-glutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours: a prospective study in the Swedish AMORIS cohort. BMC Cancer. 2018;18(1):205.","journal-title":"BMC Cancer"},{"issue":"7","key":"4985_CR10","first-page":"1487","volume":"52","author":"A Yuce","year":"2023","unstructured":"Yuce A, Keles M, Benli E, Cirakoglu A, Yazici I, Nalbant I. Comparison of Serum Gamma Glutamyl Transferase Levels between Prostate Cancer Patients and Their Healthy Peers. Iran J Public Health. 2023;52(7):1487\u201394.","journal-title":"Iran J Public Health"},{"key":"4985_CR11","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2147\/CLEP.S382116","volume":"14","author":"S Yang","year":"2022","unstructured":"Yang S, Song J, Yang H, Liu W, Jiang Y, Sun X, et al. Genetically Predicted Circulating Concentrations of Alanine and Alanine Aminotransferase Were Associated with Prostate Cancer Risk. Clin Epidemiol. 2022;14:1255\u201364.","journal-title":"Clin Epidemiol"},{"issue":"3","key":"4985_CR12","doi-asserted-by":"publisher","first-page":"e0122438","DOI":"10.1371\/journal.pone.0122438","volume":"10","author":"M Kang","year":"2015","unstructured":"Kang M, Jeong CW, Ku JH, Kwak C, Kim HH. Hypertriglyceridemia is a potential preoperative predictor for biochemical recurrence after radical prostatectomy. PLoS One. 2015;10(3):e0122438.","journal-title":"PLoS One"},{"issue":"1","key":"4985_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02561-4","volume":"20","author":"J Huang","year":"2022","unstructured":"Huang J, Zhao B, Weinstein SJ, Albanes D, Mondul AM. Metabolomic profile of prostate cancer-specific survival among 1812 Finnish men. BMC Med. 2022;20(1):362.","journal-title":"BMC Med"},{"issue":"16","key":"4985_CR14","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.2217\/fon-2016-0061","volume":"12","author":"FH Karzai","year":"2016","unstructured":"Karzai FH, Madan RA, Dahut WL. Metabolic syndrome in prostate cancer: impact on risk and outcomes. Future Oncol. 2016;12(16):1947\u201355.","journal-title":"Future Oncol"},{"issue":"2","key":"4985_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40265-022-01831-y","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ. Rezvilutamide: First Approval. Drugs. 2023;83(2):189\u201393.","journal-title":"Drugs."},{"issue":"21","key":"4985_CR16","doi-asserted-by":"publisher","first-page":"13521","DOI":"10.3390\/ijms232113521","volume":"23","author":"H Zhang","year":"2022","unstructured":"Zhang H, Zhou Y, Xing Z, Sah RK, Hu J, Hu H. Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance. Int J Mol Sci. 2022;23(21):13521.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"4985_CR17","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41416-021-01435-5","volume":"125","author":"F Ahmad","year":"2021","unstructured":"Ahmad F, Cherukuri MK, Choyke PL. Metabolic reprogramming in prostate cancer. Br J Cancer. 2021;125(9):1185\u201396.","journal-title":"Br J Cancer"},{"issue":"2","key":"4985_CR18","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/bcp.15528","volume":"89","author":"T Dai","year":"2023","unstructured":"Dai T, Xu Z, Huang L, Wang Y, Zeng G, Ye M, et al. A single-centre, open-label, single-arm, fixed-sequence pharmacokinetic study of SHR3680 on repaglinide and bupropion in prostate cancer patients. Br J Clin Pharmacol. 2023;89(2):874\u201386.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"4985_CR19","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.steroids.2013.05.001","volume":"78","author":"G Chazenbalk","year":"2013","unstructured":"Chazenbalk G, Singh P, Irge D, Shah A, Abbott DH, Dumesic DA. Androgens inhibit adipogenesis during human adipose stem cell commitment to preadipocyte formation. Steroids. 2013;78(9):920\u20136.","journal-title":"Steroids."},{"issue":"1-2","key":"4985_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.mce.2008.08.019","volume":"296","author":"V Gupta","year":"2008","unstructured":"Gupta V, Bhasin S, Guo W, Singh R, Miki R, Chauhan P, et al. Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes. Mol Cell Endocrinol. 2008;296(1-2):32\u201340.","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"4985_CR21","doi-asserted-by":"publisher","first-page":"155798831987648","DOI":"10.1177\/1557988319876488","volume":"13","author":"E Wolny-Rokicka","year":"2019","unstructured":"Wolny-Rokicka E, Tukiendorf A, Wydma\u0144ski J, Ostrowska M, Zembro\u0144-\u0141acny A. Lipid Status During Combined Treatment in Prostate Cancer Patients. Am J Mens Health. 2019;13(5):1557988319876488.","journal-title":"Am J Mens Health"},{"issue":"5","key":"4985_CR22","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen PL, Alibhai SM, Basaria S, D\u2019Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825\u201336.","journal-title":"Eur Urol"},{"issue":"1","key":"4985_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019;381(1):13\u201324.","journal-title":"N Engl J Med"},{"issue":"36","key":"4985_CR24","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO-24-01798","volume":"42","author":"F Saad","year":"2024","unstructured":"Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, et al. Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. J Clin Oncol. 2024;42(36):4271\u201381.","journal-title":"J Clin Oncol"},{"issue":"32","key":"4985_CR25","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019;37(32):2974\u201386.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4985_CR26","doi-asserted-by":"publisher","first-page":"102057","DOI":"10.1016\/j.clgc.2024.02.008","volume":"22","author":"K Dindinger-Hill","year":"2024","unstructured":"Dindinger-Hill K, Hu S, Hickman A, Choudry M, Vehawn J, Snyder J, et al. Association of Baseline Pre-Diagnosis and Post-Diagnosis Obesity and Weight Change with Cardiovascular Risk and Survival Among Nonmetastatic Prostate Cancer Survivors. Clin Genitourin Cancer. 2024;22(3):102057.","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"4985_CR27","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1002\/ijc.25739","volume":"129","author":"C Chamberlain","year":"2011","unstructured":"Chamberlain C, Romundstad P, Vatten L, Gunnell D, Martin RM. The association of weight gain during adulthood with prostate cancer incidence and survival: a population-based cohort. Int J Cancer. 2011;129(5):1199\u2013206.","journal-title":"Int J Cancer"},{"issue":"5","key":"4985_CR28","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.juro.2007.07.026","volume":"178","author":"RB Montgomery","year":"2007","unstructured":"Montgomery RB, Goldman B, Tangen CM, Hussain M, Petrylak DP, Page S, et al. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. J Urol. 2007;178(5):1946\u201351. discussion 51","journal-title":"J Urol"},{"issue":"3","key":"4985_CR29","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/s41391-021-00418-0","volume":"25","author":"A Martini","year":"2022","unstructured":"Martini A, Shah QN, Waingankar N, Sfakianos JP, Tsao CK, Necchi A, et al. The obesity paradox in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2022;25(3):472\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"24","key":"4985_CR30","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMoa2409515","volume":"391","author":"JD Groarke","year":"2024","unstructured":"Groarke JD, Crawford J, Collins SM, Lubaczewski S, Roeland EJ, Naito T, et al. Ponsegromab for the Treatment of Cancer Cachexia. N Engl J Med. 2024;391(24):2291\u2013303.","journal-title":"N Engl J Med"},{"issue":"1","key":"4985_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.urology.2006.09.039","volume":"69","author":"K Kuroda","year":"2007","unstructured":"Kuroda K, Nakashima J, Kanao K, Kikuchi E, Miyajima A, Horiguchi Y, et al. Interleukin 6 Is Associated with Cachexia in Patients with Prostate Cancer. Urology. 2007;69(1):113\u20137.","journal-title":"Urology."},{"issue":"2","key":"4985_CR32","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1006\/clin.1997.4382","volume":"84","author":"MF Muldoon","year":"1997","unstructured":"Muldoon MF, Marsland A, Flory JD, Rabin BS, Whiteside TL, Manuck SB. Immune System Differences in Men with Hypo- or Hypercholesterolemia. Clin Immunol Immunopathol. 1997;84(2):145\u20139.","journal-title":"Clin Immunol Immunopathol"},{"issue":"3","key":"4985_CR33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3109\/10715769609149049","volume":"25","author":"MF Muldoon","year":"1996","unstructured":"Muldoon MF, Kritchevsky SB, Evans RW, Kagan VE. Serum Total Antioxidant Activity in Relative Hypo- and Hypercholesterolemia. Free Radical Research. 1996;25(3):239\u201345.","journal-title":"Free Radical Research"},{"issue":"7","key":"4985_CR34","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1080\/01635581.2016.1206582","volume":"68","author":"HQ Ma","year":"2016","unstructured":"Ma HQ, Cui LH, Li CC, Yu Z, Piao JM. Effects of Serum Triglycerides on Prostate Cancer and Breast Cancer Risk: A Meta-Analysis of Prospective Studies. Nutr Cancer. 2016;68(7):1073\u201382.","journal-title":"Nutr Cancer"},{"issue":"7","key":"4985_CR35","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/sj.bjc.6605264","volume":"101","author":"H Ulmer","year":"2009","unstructured":"Ulmer H, Borena W, Rapp K, Klenk J, Strasak A, Diem G, et al. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br J Cancer. 2009;101(7):1202\u20136.","journal-title":"Br J Cancer"},{"issue":"4","key":"4985_CR36","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1464-410X.2011.10358.x","volume":"109","author":"N Hayashi","year":"2012","unstructured":"Hayashi N, Matsushima M, Yamamoto T, Sasaki H, Takahashi H, Egawa S. The impact of hypertriglyceridemia on prostate cancer development in patients aged \u226560 years. BJU Int. 2012;109(4):515\u20139.","journal-title":"BJU Int"},{"issue":"4","key":"4985_CR37","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/pcan.2011.30","volume":"14","author":"DE Kok","year":"2011","unstructured":"Kok DE, van Roermund JG, Aben KK, den Heijer M, Swinkels DW, Kampman E, et al. Blood lipid levels and prostate cancer risk; a cohort study. Prostate Cancer Prostatic Dis. 2011;14(4):340\u20135.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10","key":"4985_CR38","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrc2222","volume":"7","author":"JA Menendez","year":"2007","unstructured":"Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7(10):763\u201377.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"4985_CR39","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.coph.2012.07.006","volume":"12","author":"K Pelton","year":"2012","unstructured":"Pelton K, Freeman MR, Solomon KR. Cholesterol and prostate cancer. Curr Opin Pharmacol. 2012;12(6):751\u20139.","journal-title":"Curr Opin Pharmacol"},{"issue":"3","key":"4985_CR40","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ucl.2011.04.001","volume":"38","author":"KR Solomon","year":"2011","unstructured":"Solomon KR, Freeman MR. The Complex Interplay Between Cholesterol and Prostate Malignancy. Urol Clin North Am. 2011;38(3):243\u201359.","journal-title":"Urol Clin North Am"},{"issue":"1","key":"4985_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40170-021-00278-1","volume":"10","author":"NL Raftopulos","year":"2022","unstructured":"Raftopulos NL, Washaya TC, Niederpr\u00fcm A, Egert A, Hakeem-Sanni MF, Varney B, et al. Prostate cancer cell proliferation is influenced by LDL-cholesterol availability and cholesteryl ester turnover. Cancer Metab. 2022;10(1):1.","journal-title":"Cancer Metab"},{"key":"4985_CR42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.clnesp.2023.09.001","volume":"58","author":"U Yang","year":"2023","unstructured":"Yang U, Harikrishna A, Preda V, Chen J. Efficacy of multidisciplinary interventions in preventing metabolic syndrome and improving body composition in prostate cancer patients treated with androgen deprivation therapy: A systematic review and meta-analysis. Clin Nutr ESPEN. 2023;58:27\u201349.","journal-title":"Clin Nutr ESPEN"},{"issue":"2","key":"4985_CR43","first-page":"234","volume":"71","author":"NS Zabegalina","year":"2018","unstructured":"Zabegalina NS, Henderickx M, Lamotte V, Segers B, Stassijns G, De Wachter S, et al. Effects of a six-month supervised physical exercise program on physical and cardio-metabolic profile and quality of life in patients with prostate cancer on androgen deprivation therapy: a pilot and feasibility study. Cent European J Urol. 2018;71(2):234\u201341.","journal-title":"Cent European J Urol"},{"issue":"2","key":"4985_CR44","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1530\/ERC-15-0456","volume":"23","author":"L Teleni","year":"2016","unstructured":"Teleni L, Chan RJ, Chan A, Isenring EA, Vela I, Inder WJ, et al. Exercise improves quality of life in androgen deprivation therapy-treated prostate cancer: systematic review of randomised controlled trials. Endocr Relat Cancer. 2016;23(2):101\u201312.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"4985_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02263-x","volume":"20","author":"X Qin","year":"2022","unstructured":"Qin X, Ji D, Gu W, Han W, Luo H, Du C, et al. Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I\/II trial. BMC Med. 2022;20(1):84.","journal-title":"BMC Med"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04985-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04985-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04985-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:36:07Z","timestamp":1789688167000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04985-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4985"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04985-8","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol and all amendments were approved by the Fudan University Shanghai Cancer Center Institutional Review Board (approval number: 1802181-1) and the independent ethics committees of all participating institutions. Written informed consent was obtained from all patients before initiation of study treatment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"499"}}